121 related articles for article (PubMed ID: 37805050)
21. Patient-reported reasons for discontinuing overactive bladder medication.
Benner JS; Nichol MB; Rovner ES; Jumadilova Z; Alvir J; Hussein M; Fanning K; Trocio JN; Brubaker L
BJU Int; 2010 May; 105(9):1276-82. PubMed ID: 19912188
[TBL] [Abstract][Full Text] [Related]
22. Changes in overactive bladder medication following bariatric surgery: segmented regression analysis.
Al-Bahou J; Bhagwandass H; Valdes IL; Friedman J; Vouri SM
World J Urol; 2022 Jul; 40(7):1777-1783. PubMed ID: 35384485
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
[TBL] [Abstract][Full Text] [Related]
24. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting.
Asche CV; Kim J; Kulkarni AS; Chakravarti P; Andersson KE
BJU Int; 2012 Feb; 109(4):572-80. PubMed ID: 21777361
[TBL] [Abstract][Full Text] [Related]
25. Impact of New Medications and $4 Generic Programs on Overactive Bladder Treatment Among Older Adults in the United States, 2000-2015.
Kinlaw AC; Jonsson Funk M; Conover MM; Pate V; Markland AD; Wu JM
Med Care; 2018 Feb; 56(2):162-170. PubMed ID: 29287033
[TBL] [Abstract][Full Text] [Related]
26. Positive association of female overactive bladder symptoms and estrogen deprivation: A nationwide population-based cohort study in Taiwan.
Cheng CL; Li JR; Lin CH; de Groat WC
Medicine (Baltimore); 2016 Jul; 95(28):e4107. PubMed ID: 27428195
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
[TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
Pelletier EM; Vats V; Clemens JQ
Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
[TBL] [Abstract][Full Text] [Related]
29. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
[TBL] [Abstract][Full Text] [Related]
30. Association of Overactive Bladder With Hypertension and Blood Pressure Control: The Multi-Ethnic Study of Atherosclerosis (MESA).
Akbar A; Liu K; Michos ED; Bancks MP; Brubaker L; Markossian T; Durazo-Arvizu R; Kramer H
Am J Hypertens; 2022 Jan; 35(1):22-30. PubMed ID: 33899909
[TBL] [Abstract][Full Text] [Related]
31. Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder.
Suehs BT; Davis C; Franks B; Yuran TE; Ng D; Bradt J; Knispel J; Vassilakis M; Berner T
J Am Geriatr Soc; 2016 Apr; 64(4):779-87. PubMed ID: 27059714
[TBL] [Abstract][Full Text] [Related]
32. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women.
Geller EJ; Crane AK; Wells EC; Robinson BL; Jannelli ML; Khandelwal CM; Connolly A; Parnell BA; Matthews CA; Dumond JB; Busby-Whitehead J
Clin Drug Investig; 2012 Oct; 32(10):697-705. PubMed ID: 22873491
[TBL] [Abstract][Full Text] [Related]
33. The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications.
Welk B; Etaby K; McArthur E; Chou Q
Neurourol Urodyn; 2022 Jan; 41(1):348-356. PubMed ID: 34719044
[TBL] [Abstract][Full Text] [Related]
34. The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study.
Diamond P; Hassonah S; Alarab M; Lovatsis D; Drutz HP
Int Urogynecol J; 2012 Nov; 23(11):1577-80. PubMed ID: 22531957
[TBL] [Abstract][Full Text] [Related]
35. The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder.
Suehs BT; Caplan EO; Hayden J; Ng DB; Gaddy RR
Drugs Aging; 2019 Oct; 36(10):957-967. PubMed ID: 31359329
[TBL] [Abstract][Full Text] [Related]
36. Risk of overactive bladder associated with cholinesterase inhibitors in dementia.
Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
J Am Geriatr Soc; 2022 Mar; 70(3):820-830. PubMed ID: 34854475
[TBL] [Abstract][Full Text] [Related]
37. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
[TBL] [Abstract][Full Text] [Related]
38. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the prevalence of and factors associated with overactive bladder in adult Korean women.
Kim SY; Bang W; Choi HG
PLoS One; 2017; 12(9):e0185592. PubMed ID: 28957446
[TBL] [Abstract][Full Text] [Related]
40. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
